Shinya Yamanaka won the 2012 Nobel Prize for showing that four transcription factors, Oct4, Sox2, Klf4, and c-Myc (OSKM), can revert somatic cells to a pluripotent state. Full reprogramming creates induced pluripotent stem cells. Partial reprogramming aims for something more targeted: resetting the epigenetic clock without erasing what the cell does for a living. Old cells become young cells of the same type.

Ocampo et al. (2016) tested this in a progeria mouse model. Cyclic expression of OSKM reversed aging hallmarks and extended lifespan by 30%. But progeria is an accelerated aging disease. The question that mattered for the rest of us: could partial reprogramming rejuvenate normal, old animals?

David Sinclair's lab answered that in 2020. Lu et al., published in Nature, used adeno-associated virus (AAV) to deliver three factors, Oct4, Sox2, and Klf4 (OSK, dropping the oncogene c-Myc), to retinal ganglion cells of aged mice. The treatment restored youthful DNA methylation patterns and gene expression, regenerated damaged optic nerves, and brought back vision. One tissue, one function, proof of concept.

This new study goes systemic. An inducible OSK transgenic system was switched on for 2 days, then off for 5 days, cycling for 7 months in 22-month-old mice (roughly 70 human years). Skeletal muscle satellite cells recovered their regenerative capacity, producing 2.3-fold more new myofibers after injury compared to untreated aged controls. Liver albumin levels returned to values seen in 6-month-old mice.

Epigenetic clock analysis using the Meer et al. (2018) murine clock showed an average biological age reduction of 8.3 mouse-equivalent years. Single-cell RNA sequencing painted a consistent picture: treated tissues had gene expression profiles midway between aged and young controls, with the largest shifts in inflammation (NF-κB targets down 41%), mitochondrial function (oxidative phosphorylation genes up 28%), and proteostasis (autophagy genes up 35%).

No teratomas or neoplasms appeared in any treated animal over the full study period. The cyclic dosing schedule appears to be the key safety feature. Continuous expression pushes cells toward dangerous dedifferentiation. Intermittent pulses reset the epigenome without destabilizing cell fate. Lineage tracing confirmed that reprogrammed cells stayed true to their tissue identity throughout treatment.

Treated mice lived 30% longer than age-matched untreated controls (P < 0.001). Altos Labs, NewLimit, and other biotech companies are building delivery systems for human translation. The main engineering challenge: achieving targeted, controllable, transient expression of reprogramming factors in specific tissues without viral vectors.